Atara Biotherapeutics turns to Q1 FY26 net loss of $4.1 million; revenue falls to $516,000

• Atara Biotherapeutics posted a first-quarter net loss of $4.1 million, swinging from net income of $38 million a year earlier; loss per share was $0.29.
• Revenue plunged to $516,000 from $98.15 million, as the prior-year quarter included a one-time acceleration tied to transfer of tab-cel manufacturing responsibilities to Pierre Fabre Laboratories on March 31, 2025.
• Operating cash burn narrowed to $3.1 million from $28.1 million, while cash, cash equivalents and short-term investments totaled $8.4 million at March 31.
• Pierre Fabre, with Atara support, held a meeting with FDA on a path to resubmit tab-cel BLA; FDA agreed a single-arm study using a pre-specified historical control could support a marketing application, with a further regulatory update expected in Q3.
• Cash runway extended into mid-2027, based on March 31 cash plus $4.8 million of ATM proceeds raised after quarter end and operating efficiencies implemented in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605121605BIZWIRE_USPR_____20260512_BW257848) on May 12, 2026, and is solely responsible for the information contained therein.